Yale Cancer Center Researchers Awarded Grants by Breast Cancer Research Foundation
The Breast Cancer Research Foundation (BCRF) Scientific Advisory Board and its Board of Directors recently announced its 2022 research grants, including six funded grants at Yale Cancer Center and Smilow Cancer Hospital awarded to Mehra Golshan, MD, MBA, Melinda Irwin, PhD, MPH, Ian Krop, MD, PhD, Lajos Pusztai, MD, DPhil, David Rimm, MD, PhD, and Eric Winer, MD to support their research.
Breast Cancer: Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies
In HER2-positive early stage (stage I-II) breast cancer, several different preoperative (also called neoadjuvant) chemotherapy options exist, each of these is associated with a different rate of complete eradication of cancer from the breast and lymph nodes (called pathologic complete response or pCR). Patients who experience pCR have excellent long term survival.Source: MedicalResearch.com
SWOG Cancer Research Network Study Opens Window into Immune Microenviroment
The first comprehensive study of immune cell types in pre- and post-chemotherapy cancer tissues points up a host of targets for new or existing cancer drugs that could improve patients’ sensitivity to both chemotherapy and immunotherapy.Source: Bioengineer.org
New Haven cancer doctors working to draw people of color into clinical trials
Minorities make up about 10 percent to 12 percent of the participants in clinical trials at Smilow, which recruits participants from across Connecticut, said Dr. Roy Herbst, chief of medical oncology. But, given that New Haven is about two-thirds black or Hispanic, both Herbst and Silber would like to increase the number of minorities who can benefit from new drugs. “We want to bring the best care to all people; we want to bring access to all people,” said Herbst, who said he’d like to at least double the percentage of minorities in Smilow’s trials of cancer drugs.Source: New Haven Register
Subtype of triple negative breast cancer responds better to chemotherapy
Researchers at Yale Cancer Center have identified a new subtype of triple negative breast cancer that shows significantly improved response to chemotherapy. Patients with the newly defined subtype — BRCA-deficient triple negative breast cancer — had significantly higher survival rates with chemotherapy.
Large Gene Network Required to Predict Response to HER2-Targeted Therapy
It is unlikely that any single gene can predict response to targeted therapy for patients with HER2-positive breast cancer, new findings from a study suggest. Instead, gene networks— specifically those involving PI3 kinase (PI3K)—may provide a clearer picture of patient outcomes.Source: OncLive
Dr. Lajos Pusztai named Susan G. Komen Scholar and Awarded Leadership Grant
Yale Cancer Center scientist and physician Lajos Pusztai, M.D., has been named to a group of breast cancer leaders from around the world advising Susan G. Komen on the organization’s multiple endeavors. Pusztai, professor of medicine (medical oncology); chief of breast medical oncology; and co-director of Yale Cancer Center’s genetics, genomics and epigenetics program, is one of just 44 breast cancer experts to receive the honor since 2010.
Immunotherapy Trial for Triple Negative Breast Cancer
In late 2015, Yale Cancer Center launched a clinical trial using an immunotherapy drug for patients with early-stage triple negative breast cancer (TNBC), a less common and aggressive type of breast cancer. In the Q&A below, Principal Investigator, Lajos Pusztai, MD, chief of breast medical oncology, discusses the trial and the potential of immunotherapy for treating breast cancer.
Text Messaging Helps Keep Women Compliant with Aromatase Inhibitor Therapy
Using an investigative telephone text messaging protocol, clinicians were able to help women diagnosed with breast cancer remain on their endocrine therapy and get them through often difficult musculoskeletal adverse events, researchers reported here.Source: Oncology Times
Study links body fat, weight loss, and chromosome length in breast cancer patients
It is well documented that a healthy diet and exercise are key in cancer prevention and management, but the exact mechanism hasn’t been clear. Now, Yale Cancer Center researchers have found an explanation in the tiny protective ends of chromosomes called telomeres. The findings were presented Dec. 11 at the 2015 San Antonio Breast Cancer Symposium.
Yale: Black Women With Breast Cancer Less Likely To Benefit From Early Chemo
Black women with breast cancer fare worse than other women when treated with early chemotherapy, according to new research from the Yale Cancer Center. Typically, black, Hispanic and Asian women are more likely to undergo neoadjuvant chemotherapy, or chemotherapy prior to surgery, than white women because they are more likely to develop advanced-stage breast cancer. But the new study found that black women are less likely to benefit from the treatment.Source: C-Hit
Yale Cancer Center Experts Present New Research at Hematology Annual Meeting
Physicians and scientists from Yale Cancer Center, part of Yale School of Medicine, will present new research at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, Calif., from December 9 to 12.
Yale Researchers Develop New Testing Criteria for Hereditary Stomach Cancer
Yale researchers have shown that individuals who carry a mutation in the CDH1 gene have a 30% to 40% risk of developing stomach cancer during their lifetime. Yet many people with the rare inherited condition remain unaware that they have it.
Yale scientists chosen by White House to expedite cancer research
Yale is one of three institutions that have been honored with the White House Cancer Moonshot research grant. Yale's Douglas Hanlon, PhD, research scientist in dermatology, and Richard Edelson, MD, the Anthony N. Brady Professor of Dermatology, describe their groundbreaking research, using mRNA technology to create a vaccine that targets only cancer cells.Source: WTNH News 8
YSPH alumna Margaret Mayer embraces challenge of grant management at the National Cancer Institute
This Alumni Spotlight focuses on Margaret Mayer, PhD ’19 (Chronic Disease Epidemiology), MPH ’16 (Chronic Disease Epidemiology), the program director in the Tobacco Cancer Research Branch at the National Cancer Institute.
Overdiagnosis and Preventative Screening: A Q&A With Ilana Richman
In a Q&A, Ilana Richman, MD, MHS, assistant professor of medicine (general medicine), discusses why overdiagnosis is a concern, the challenges of assessing the benefit of new screening technologies, and the risks and benefits people should weigh when considering preventative screening.
Sang Taek Kim Returns to YSM to Lead Immunotherapy Adverse Events Program
A physician scientist, Sang Taek Kim, MD, PhD, assistant professor of medicine (rheumatology), is interested in the autoimmune complications induced by cancer immunotherapy. In his new role, he serves as director of the Immunotherapy Adverse Events in Rheumatology Program.